Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, discusses principal findings of the PROpel trial, which compared outcomes between olaparib plus abiraterone vs abiraterone alone in men with metastatic castration-resistant prostate cancer (mCRPC).
The ongoing PROpel trial investigated olaparib (Lynparza; AstraZeneca, Merck Sharp & Dohme) plus abiraterone (Zytiga; Janssen) vs abiraterone alone in men with metastatic castration-resistant prostate cancer, a patient group with a low 5-year survival rate who typically receives just 1 line of active treatment. The results presented at this year’s American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) demonstrate the combination’s quality-of-life and radiographic progression-free survival (rPFS) benefits; chiefly that it reduced risk of the latter by 34%. Overall rPFS was 24.8 vs 16.6 months, respectively, and there was a trend toward improved overall survival.
The American Journal of Managed Care® spoke recently with Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, about the PROpel trial findings presented at this year’s American Society of Clinical Oncology Genitourinary Cancers Symposium.
Transcript
Can you summarize the findings of the PROpel trial?
PROpel is a large randomized phase 3 trial, which included patients with first-line metastatic castrate-resistant prostate cancer, that we call mCRPC, that included a patient population which was not selected based on their HRR gene mutation status. PROpel was presented at ASCO GU and showed that olaparib in combination with abiraterone led to statistically significant and clinically meaningful improvements in radiographic PFS, which was a primary end point, with a reduction by 34% of the risk of disease progression or death in patients treated with olaparib and abiraterone compared to abiraterone plus placebo in the first-line setting.
Olaparib in combination with abiraterone improved radiographic PFS with a median of 8 months, extending the median rPFS for these first-line with metastatic castrate-resistant prostate cancer patients beyond 2 years. This is the longest PFS benefit seen to date in this setting. Importantly, this PFS benefit reported for olaparib plus abiraterone was irrespective of HRR gene mutation status.
I’d like also to note that the safety profile of the combination was consistent with the safety profile of each individual drug and the quality of life was maintained in the arm with olaparib plus abiraterone.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More